JP2023549761A5 - - Google Patents
Info
- Publication number
- JP2023549761A5 JP2023549761A5 JP2023527977A JP2023527977A JP2023549761A5 JP 2023549761 A5 JP2023549761 A5 JP 2023549761A5 JP 2023527977 A JP2023527977 A JP 2023527977A JP 2023527977 A JP2023527977 A JP 2023527977A JP 2023549761 A5 JP2023549761 A5 JP 2023549761A5
- Authority
- JP
- Japan
- Prior art keywords
- syndrome
- disease
- protein
- nuclear protein
- target nuclear
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063110616P | 2020-11-06 | 2020-11-06 | |
| US63/110,616 | 2020-11-06 | ||
| PCT/US2021/058276 WO2022099025A1 (en) | 2020-11-06 | 2021-11-05 | Nuclear protein targeting engineered deubiquitinases and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023549761A JP2023549761A (ja) | 2023-11-29 |
| JP2023549761A5 true JP2023549761A5 (cg-RX-API-DMAC7.html) | 2024-11-08 |
Family
ID=81456815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023527977A Pending JP2023549761A (ja) | 2020-11-06 | 2021-11-05 | 核タンパク質ターゲティング操作脱ユビキチン化酵素およびその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240026329A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4240751A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023549761A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117222660A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021374981A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3200977A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022099025A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3200980A1 (en) * | 2020-11-06 | 2022-05-12 | Flux Therapeutics, Inc. | Cytosolic protein targeting engineered deubiquitinases and methods of use thereof |
| CN116396965B (zh) * | 2023-03-01 | 2024-03-19 | 北京市心肺血管疾病研究所 | Ahdc1在构建肥胖动物模型中的应用及方法和药物筛选方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9388213B2 (en) * | 2012-09-10 | 2016-07-12 | The Rockefeller University | Polycomb repressive complex 2 (PRC2) inhibitors and uses thereof |
| GB201714718D0 (en) * | 2017-09-13 | 2017-10-25 | Autolus Ltd | Cell |
| EP3706782A4 (en) * | 2017-11-06 | 2021-09-08 | The Trustees of Columbia University in the City of New York | COMPOSITIONS AND METHODS OF USING MANIPULATED DEUBIQUITINASES FOR PROBING UBIQUITIN-DEPENDENT CELL PROCESSES |
| WO2019126762A2 (en) * | 2017-12-22 | 2019-06-27 | The Broad Institute, Inc. | Cas12a systems, methods, and compositions for targeted rna base editing |
| AU2020224327B2 (en) * | 2019-02-21 | 2022-09-29 | Entact Bio Limited | Survival-targeting chimeric ( SURTAC) molecules |
| EP4048316A1 (en) * | 2019-10-21 | 2022-08-31 | Translate Bio, Inc. | Compositions, methods and uses of messenger rna |
-
2021
- 2021-11-05 WO PCT/US2021/058276 patent/WO2022099025A1/en not_active Ceased
- 2021-11-05 JP JP2023527977A patent/JP2023549761A/ja active Pending
- 2021-11-05 AU AU2021374981A patent/AU2021374981A1/en active Pending
- 2021-11-05 US US18/251,836 patent/US20240026329A1/en active Pending
- 2021-11-05 EP EP21890160.1A patent/EP4240751A4/en active Pending
- 2021-11-05 CN CN202180089135.8A patent/CN117222660A/zh active Pending
- 2021-11-05 CA CA3200977A patent/CA3200977A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102533834B1 (ko) | 개질된 미토콘드리아 및 이의 용도 | |
| ES2871899T3 (es) | Péptidos antiinflamatorios y composición que comprende a los mismos | |
| JP2020096630A5 (cg-RX-API-DMAC7.html) | ||
| EP1301605B1 (en) | Nk cells activating receptors and their therapeutic and diagnostic uses | |
| WO2021213421A1 (zh) | 融合蛋白分子及其制备方法和用途 | |
| JP2026074003A (ja) | B7h3標的タンパク質及びその使用方法 | |
| EP1502949B1 (en) | Antimicrobial polypeptide and utilization thereof | |
| KR20030048041A (ko) | 표적-특이적 프로드럭으로서 사용하기 위한항체-사이토카인-사이토카인 억제제로 이루어진 융합단백질(셀렉토카인) | |
| AU2001278662A1 (en) | NK cells activating receptors and their therapeutic and diagnostic uses | |
| WO2023036246A1 (zh) | 一种转基因免疫效应细胞及其应用 | |
| CA3180251A1 (en) | Cytokine conjugates | |
| US20260132180A1 (en) | Oncoselective therapy | |
| WO2017061354A1 (ja) | 遺伝子発現用カセット及びその産生物 | |
| JP2023548973A5 (cg-RX-API-DMAC7.html) | ||
| KR20220007619A (ko) | 면역조절 조성물 및 방법 | |
| JPH06220099A (ja) | 可溶性ldlリセプター | |
| JP2023549167A5 (cg-RX-API-DMAC7.html) | ||
| JP6871679B2 (ja) | 遺伝子発現用カセット及びその産生物 | |
| US20240317831A1 (en) | Nk cell engager molecules and methods of use | |
| CN106496329B (zh) | 一种含有胶原蛋白结合结构域的融合蛋白 | |
| CA3225734A1 (en) | Chimeric klebicins | |
| JP2017070224A (ja) | 遺伝子発現用カセット及びその産生物 | |
| JP2023551068A5 (cg-RX-API-DMAC7.html) | ||
| TW202144579A (zh) | 病毒載體在冠狀病毒疫苗生產的用途 | |
| KR20200069253A (ko) | 인간 항-antxr 키메라 항원 수용체 및 이의 용도 |